Evaluating the economic impact of screening and treatment for depression in the workplace by Evans-Lacko, Sara et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.euroneuro.2016.03.005
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Evans-Lacko, S., Koeser, L., Knapp, M., Longhitano, C., Zohar, J., & Kuhn, K. (2016). Evaluating the economic
impact of screening and treatment for depression in the workplace. European Neuropsychopharmacology, 26(6),
1004–1013. 10.1016/j.euroneuro.2016.03.005
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 01. May. 2017
1 
 
Citation: Evans-Lacko S, Koeser L, Knapp M, Longhitano C, Zohar J, Kuhn K. Evaluating the economic 
impact of screening and treatment for depression in the workplace. Eur Neuropsychopharmacol 
2016; published online April 13. DOI:10.1016/j.euroneuro.2016.03.005. 
CC BY NC ND 
Title: Evaluating the economic impact of screening and treatment for depression in the workplace 
Sara Evans-Lacko1,2, Leonardo Koeser2, Martin Knapp1, Calogero Longhitano3, Joseph Zohar4, Karl 
Kuhn5, 6 
1 London School of Economics and Political Science, London, United Kingdom 
2 Institute of Psychiatry, Psychology & Neuroscience, King’s College London 
3 South London and Maudsley NHS Foundation Trust 
4 Expert Platform on Mental Health – Focus on Depression, Tel-Aviv, Israel 
5 German GIZ, German Ministry for Development 
6 Griffith University, Brisbane, Australia 
Corresponding Author Full Contact Details: 
Sara Evans-Lacko, PhD 
Personal Social Services Research Unit 
London School of Economics and Political Science 
Houghton Street 
London 
WC2A 2AE 
2 
 
Telephone:  + 44 (0) 20 7955 6028 
Email: S.Evans-Lacko@lse.ac.uk 
Word count:  (excluding abstract, tables/figures and references): 5,357 
  
3 
 
Abstract  
Depression is the most common psychiatric illness and cause of disability, and associated with 
durable impacts on productivity and represents one of the major causes of workplace absenteeism 
and presenteeism. Few studies, however, examine the economic impact of treatment of depression 
in the workplace, particularly from the perspective of the employer. We estimated the relative cost-
effectiveness of treatment for employees with depression in the workplace. We used a decision-
analytic model to estimate the relative cost-effectiveness of (i) psychotherapy, (ii) pharmacotherapy 
and (iii) combination of psychotherapy and pharmacotherapy and whether they reduce sickness, 
absenteeism and presenteeism for people with depression. Costs and savings to the employer were 
also estimated, and policy recommendations made about how best to translate this evidence into 
practice. Both pharmacotherapy treatment and psychotherapy treatment were found to be cost-
saving from the perspective of the employer. Psychotherapy was found to be the most cost-effective 
option with an incremental cost-effectiveness ratio of €22,225. This study provides evidence that 
screening and treatment for depression in the workplace is cost-effective and represents a 
worthwhile investment from the business perspective.  
 
 
Key words: depression, employment, cost-effectiveness, economic evaluation, mental illness  
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Introduction 
Depression is the most common psychiatric illness and cause of disability, ranking as the second 
leading cause of disability worldwide (Ferrari et al., 2013). In addition to the significant social and 
personal consequences, depression is associated with durable impacts on productivity and 
represents one of the major causes of workplace absenteeism and presenteeism. Depression in 
working age adults generates direct costs in the field of health services and indirect costs from lost 
working hours, loss of lifetime income, and early retirement. By far the greatest contributor to the 
overall economic impact of depression is loss in productivity and this represents a substantial cost to 
employers (Ekman et al, 2013; Thomas, 2003). It is estimated that the total productivity costs of 
absenteeism due to mood disorders in the EU-25 is €72 billion in 2010 prices  –about twice that of 
cardiovascular disease (Gustavsson et al., 2011; Leal et al., 2006). This equates to approximately €454 
per employed person in the EU at that time.  
In high-income countries, trends suggest that sick days lost to mental health problems such as 
depression have increased in recent years (Henderson and  Madan, 2014). In the past twenty 
years, in Germany, the contribution of mental disorders to the cost of permanent disability 
pensions has tripled and more than half of these are caused by depression, anxiety and related 
neurotic disorders (Techniker Krankenkasse, 2013). 
 
Several studies demonstrate effectiveness and cost-effectiveness of treatment for depression 
(Churchill et al., 2001; Hollinghurst et al., 2014; Koeser et al., , et al., 2015; NCCMH, 2009); but, 
these are mainly population-based studies which examine the outcomes from the perspective of 
the healthcare system and there are only a limited number of programmes which focus 
specifically on depression in the workplace and incorporate a robust evaluation (Hamberg-van 
Reenen et al., 2012). Given the growing impact of depression in the workplace, German data 
suggest that there has been nearly a 70% increase in workplace absenteeism associated with 
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depression between 2000 and 2013 (Techniker Krankenkasse, 2013). It is important for businesses 
to understand the economic case for recognition and treatment of depression among their 
employees and to help employers better understand their potential role in this process. There are 
only a limited number of businesses, however, which currently participate in workplace mental 
health programmes (Wolf, 2010). 
 
We explore the cost-effectiveness of treatment for employees with depression in the workplace. We 
use a decision-analytic model based on the best available evidence synthesised from the literature 
to estimate the relative cost-effectiveness of (i) psychotherapy, (ii) pharmacotherapy and (iii) 
combination of psychotherapy and pharmacotherapy and whether they reduce sickness, 
absenteeism and presenteeism for people with mild, moderate and severe depression. The net cost 
to the employer is also estimated from the employer perspective. Finally, policy recommendations 
are made about how best to translate this evidence into practice.  
 
Experimental procedures 
Study population and data source 
The target population is employed adults living in Germany with mild (F32.0, F33.0), moderate 
(F32.1, F33.1) or severe major depressive disorder (F32.2/F32.3, F33.2/F33.3) based on ICD-10 
diagnoses. Population characteristics and costs were based on the 2013 Depression Atlas report of 
the Techniker Krankenkasse (Techniker Krankenkasse, 2013) which summarises aggregated and 
anonymised administrative data collected from health insurance companies in Germany. The data 
come from 4.1 million insured individuals in the labour force in Germany and estimates were then 
extrapolated based on weighted averages to provide national estimates for the 37.8 million insured 
and employed individuals in Germany aged 15-64 years of age. Variables which were not available 
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from the report were estimated based on national epidemiological data from Germany, and / or the 
most robust trial or meta-analyses available.  
 
Model structure 
To evaluate the cost-effectiveness of treatment for employees with depression in the workplace, we 
adapted a decision model previously described by Koeser et al which compares the cost-
effectiveness of – drugs for depression, psychotherapy and a combination of –drugs for depression 
and psychotherapy treatment (Koeser et al.,, 2015) from the perspective of the healthcare system in 
England. Three potential clinical outcomes were modelled: full remission, partial response and non-
response. Model parameters related to treatment outcomes were informed by a review of the 
literature and synthesis through meta-analyses and are described in Koeser et al (Koeser et al., , 
2015). Further information on the model is also described in Figure 1.  
 
The main model assumes a 27-month time horizon: 3 months of acute treatment, 12 months of 
maintenance treatment and 12 months of follow-up. These intervals were based on the time frame 
used for the majority of trials from which the model input parameters were derived. We also, 
however, examined a time frame of 4 months and 21 months of maintenance treatment for the 
pharmacotherapy condition (i.e., 7 months and 24 months total including acute treatment) and 8 
months and 21 months for psychotherapy. The minimum time frame for the psychotherapy and 
combination therapy conditions was based on the range of time recommended in the German 
Society for Psychiatry, Psychotherapy, and Neurology (DGPPN) guidelines for unipolar depression 
(2015) and the upper limit (24 months) reflected the maximum amount of time for which German 
insurance companies would pay.  
 
Costs associated with treatment, service use and productivity losses and / or gains were calculated 
based on the presumed underlying depression state, and are detailed below. While everyone began 
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the treatment pathway in the non-response state, it was assumed that if the treatment was 
successful that the individual would enter into remission at month three while those with partial 
response would spend half of their time in remission and those with no response would never enter 
remission and thus, service use and productivity estimates reflected these varying depression states. 
 
Costs 
Cost of screening, assessment and treatment 
We estimated that €39.94 covered the cost of facilitating the completion of the screening 
questionnaire  follow-up assessment to confirm depression, and care management costs for each 
employee (McDaid et al., 2011) and that 66% of employees would follow-up with treatment 
following the screening process  Based on nationally representative epidemiological data from 
Germany, we estimated that 7.5% of employees would meet criteria for a depression diagnosis 
(Jacobi et al., 2014).  The cost of treatment was based on the recommended number of visits 
included in the guidelines for unipolar depression established by the German Society for Psychiatry, 
Psychotherapy, and Neurology (DGPPN) (2015) . The guidelines suggest that during the acute phase, 
individuals should receive one surveillance visit per week for three to four weeks and clinical 
monitoring every two to four weeks for the rest of the acute phase. The maintenance phase involves 
clinical monitoring every four to eight weeks. It is recommended that for –a drug for depression -
that the duration of the maintenance phase is four to nine months. The recommended maintenance 
phase for psychotherapy is longer, i.e., eight to twelve months. For the pharmacotherapy condition, 
we also included prescription costs (e.g., cost of a 20mg daily dose of citalopram, which was the 
most commonly drug prescribed -for people with depression according to the 2013 Depression Atlas 
report of the Techniker Krankenkasse (Techniker Krankenkasse, 2013). Costs were based on the 
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official German publisher of medical classifications Deutsches Institut fur Medizinische 
Dokumentation und Information (2015).  
We assumed that individuals with mild depression received the lower bound for the number of 
treatment visits and that all visits occurred with a primary care practitioner (rather than a 
psychiatrist). We assumed that individuals with severe depression received the upper bound in 
terms of number of recommended treatment visits and we used the median of these two estimates 
for individuals with moderate depression. For the pharmacotherapy condition, individuals with 
moderate depression were assumed to have half of their appointments with a GP and half with a 
psychiatrist while individuals with severe depression were assumed to have ninety percent of their 
appointments with a psychiatrist. The cost of each visit was estimated using the costs for treatment 
as described in Kassenarztliche Bundesvereinigung (2015a, 2015b). The cost for combination therapy 
in our model was the sum of the cost of pharmacotherapy and psychotherapy. 
Cost of additional service use 
Health service utilisation and associated costs, outside of those included in the treatment costs were 
based on estimates calculated by Kleine-Budde et al. who analysed insurance claims data for 
individuals with a diagnosis of depression from the German insurer AOK Plus between the years 
2007 and 2009 (Kleine-Budde et al., 2013). These included inpatient hospitalisation costs which were 
extrapolated over the entire 27-month period and also outpatient primary care and psychiatric care 
costs following the 15 month treatment phase for those who did not achieve remission. All 
estimates were calculated according to varying depression severity (i.e., mild, moderate and severe) 
and accounted for the underlying depression state (i.e., remission, partial response and non-
response) and were converted to 2013 costs. 
Productivity losses  
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Costs associated with absenteeism were based on data collected from the 2013 Depression Atlas 
report of the Techniker Krankenkasse (Techniker Krankenkasse, 2013) which collected data on days 
taken off because of depression. It is estimated that 1.6% took time off because of their depression 
in Germany in 2013 and that on average those individuals took 64 days off (i.e., 33, 74 and 111 days 
per year for mild, moderate and severe depression, respectively) over a one year period. As 
presenteeism data were not available from the Depression Atlas, we used based estimates on a trial 
from Wang et al (2006). Thus, it was estimated that the reduction in presenteeism as a result of 
successful intervention was equivalent to an extra 2.6 hours of work per week. Wang et al. noted 
that there were no significant differences in impact on presenteeism following treatment according 
to depression severity (i.e., there was the same increase in number of hours following treatment 
across severity) and so we assumed the same impact across groups. Again based on estimates from 
nationally representative German epidemiological data, we assumed that 7.5% of individuals would 
meet criteria for depression and experience an impact on their presenteeism associated with the 
condition  (Jacobi et al., 2014). As per the human capital approach, productivity losses were 
converted to costs based on the average gross added value per worker in Germany in 2013 (€66,448) 
based on the 2013 report of the Techniker Krankenkasse (Techniker Krankenkasse, 2013) 
Health-related quality of life 
Quality adjusted life years (QALYs) were used as an indicator of health-related quality of life. Current 
NICE guidelines recommend using the EuroQol 5 Dimensions (EQ-5D) when deriving preference 
weights for health states (NICE, 2013); however, there is no published evidence which is currently 
available, mapping EQ-5D scores by depression status as defined by the HAMD-17 in this model. 
Therefore,  we used estimates from Koeser et al., as the authors calculated mean EQ-5D utilities for 
remitters, responders and non-responders as defined above based on previously collected trial data 
(Kuyken et al., 2008). To account for the fact that repeated measures were available for most 
patients, a pooled ordinary least squares model with cluster robust standard errors was used. The 
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same quality of life was assigned to individuals dropping out of treatment due to side effects or no 
response as to those who completed the treatment but who did not respond. 
Analysis  
Incremental cost-effectiveness ratios were calculated by dividing the difference in total costs of the 
treatments by the mean difference in QALYs. To reflect the current value of the benefits and costs 
accumulating over the time horizon of the model we discounted both at a rate of 3.4% as  
recommended for Germany (Gollier, 2011). We undertook sensitivity analyses to consider various 
treatment time frames, as described above, in relation to the minimum time frame recommended in 
the DGPPN guidelines for unipolar depression (2013) and the upper limit (24 months) reflected the 
maximum amount of time for which the insurance company would pay. We also compared findings 
when mild depression was and was not included.  
For the cost-effectiveness analysis, we estimated productivity losses during the first fifteen months 
alongside treatment. Productivity losses were treated equivalently to cost of health service use for 
year 1, dependent on the depression state but not treatment. For the cost-offset analysis, we also 
used a conservative timeframe and estimated the impact of depression treatment on absenteeism 
and presenteeism over a one-year period. Based on -Kuyken et al., (2008) we assumed that the gain 
was slightly lower for those treated with pharmacotherapy vs. psychotherapy (i.e., 0.097). 
We present the cost and payoffs from employer and healthcare perspectives for screening and 
treatment of employees with depression for a hypothetical cohort of 500 employees over a 27 
month timeframe. We assume for this analysis that the intervention was for 15 months, 7.5% of 
individuals screened positive for depression and that (based on nationally representative data from 
the National Comorbidity Survey in the USA) among those with depression, the prevalence of mild, 
moderate and severe depression was 13.8%, 38.5% and 47.7%, respectively (Birnbaum et al., 2010). 
As in the cost-effectiveness analysis, costs and benefits were estimated based on 50% being full 
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responders, 22% being partial responders and 28% being non-responders for CBT and 52% being full 
responders, 23% being partial responders and 25% being non-responders for pharmacotherapy. 
Results are presented so that costs or expenditures associated with the treatment are shown with a 
plus sign, while savings or reductions in costs are shown with a minus sign.  
 
Results 
Cost-effectiveness analysis 
Table 1 describes the incremental cost-effectiveness ratios for psychotherapy, pharmacotherapy and 
combination (psychotherapy and pharmacotherapy). As shown in table 1, our estimates suggest that 
pharmacotherapy had the lowest average cost (€30,598: treatment and service use costs: €5,895 
and productivity costs: €24,703) while combination pharmacotherapy and psychotherapy had the 
highest average cost (€32,615: treatment and service use costs: €7,175 and productivity costs: 
€25,540).   
In terms of outcomes, pharmacotherapy was associated with the lowest QALYs (1.26) while 
psychotherapy and combination pharmacotherapy and psychotherapy were almost equivalent (1.30 
and 1.31, respectively). The incremental cost-effectiveness ratio for improvement in QALY score at 
27 months suggested that psychotherapy was the most cost-effective option, using a commonly 
used willingness to pay threshold of (€50,000) based on NICE guidance as there is not an established 
threshold in Germany, although some authors have argued that at least for high income countries, 
societal willingness to pay may be higher (Speight and Reaney, 2009; Ubel et al., 2003). Sensitivity 
analysis which estimated results using varying time frames suggested that the costs narrowed 
slightly for the combination treatment and psychotherapy for the shorter time frame intervention 
(i.e. 7 months); however, the incremental cost-effectiveness ratio (ICER) did not change significantly. 
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Similarly for the longer time frame (i.e., 15 months intervention) there were no significant increases 
in the ICERs.  
TABLE 1 ABOUT HERE 
Cost-offset analysis from the perspective of the employer 
Table 2 summarises the net cost for pharmacotherapy, psychotherapy and combination 
pharmacotherapy and psychotherapy among a hypothetical population of 500 employees people 
and then extrapolated to the entire population of employed persons in Germany, over a 27 month 
time frame. It is assumed that the costs of screening and treatment for depression are borne by the 
employer.  The results show that from the perspective of the employer, both pharmacotherapy and 
psychotherapy appear to be cost-saving, despite the cost of needing to screen all employees. As we 
did not have absenteeism and presenteeism data specifically for combination treatment, we have 
not presented results for this condition here; however, if psychotherapy and pharmacotherapy 
intervention costs were added together (subtracting one set of screening costs) the intervention 
costs plus additional healthcare intervention costs would be approximately €101,944, which is only 
€1,000 to €2,000 greater than the projected gains in productivity.  Benefits are gained mainly from a 
reduction in presenteeism.  
 
TABLE 2 ABOUT HERE 
Discussion 
This study provides evidence that screening and treatment for depression in the workplace is cost-
effective and represents a worthwhile investment from the business perspective. It adds to the 
existing literature supporting the economic case for employers to invest in interventions to address 
depression in the workplace (Goldberg and Steury, 2001; Knapp et al., 2011; McDaid, 2008), 
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particularly in the area of prevention and treatment (Hamberg-van Reenen et al., 2012) .  Both 
pharmacotherapy treatment and psychotherapy treatment were found to be cost-saving from the 
perspective of the employer. 
Despite the lower overall cost associated with pharmacotherapy, psychotherapy was found to be the 
most cost-effective option. It may be that the durability of the outcomes associated with 
psychotherapy treatment in the long term allow for greater improvement in workplace productivity 
when compared with pharmacotherapy. A recent clinical trial also demonstrated greater 
improvement in employment status for cognitive therapy when compared with pharmacotherapy at 
two years follow up (Fournier et al., 2015).  Cognitive changes and cognitive skills acquisition as well 
as cognitive restructuring, tackling negative thoughts that prevent return to employment, have all 
been suggested as potentially putative mechanisms underpinning the effectiveness of cognitive 
therapy (DeRubeis et al., 1990; Quilty et al., 2008).  It might also be that cognitive therapy could 
promote coping skills which might hence confer long protection against relapse when compared to 
pharmacotherapy.  
In a condition as complex as depression; however, personalised treatment which is tailored to the 
needs and preferences of individuals should be considered, in line with expert recommendations 
(Wykes et al., 2015). Although offering an array of treatment options may be most useful for 
improving outcomes across a diverse population of persons with depression  (Rush et al., 2006) , our 
findings suggest that psychotherapy was likely to be the most cost-effective option when compared 
with pharmacotherapy or combination pharmacotherapy and psychotherapy. Other authors have 
also suggested that psychotherapy is likely to be more cost-effective from the perspective of the 
health system (Koeser et al., 2015). It may be that certain treatments are more effective for 
individuals based on sociodemographic characteristics;  clinical characteristics such as type of 
depression, chronicity or severity and individual values (Cuijpers et al., 2012).  Although economic 
evaluation can provide evidence to inform decisions about how to allocate available resources so as 
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to get more out of them, any one treatment should not be ruled out based on cost alone.  Other 
reviews suggest that getting individuals with depression to participate in some type of therapy with 
demonstrated effectiveness may be more important than type of treatment and this may depend 
heavily on what is readily accessible in the individual’s context (Khan et al., 2012). 
When considering the cost-effectiveness of these interventions, we assumed that only a proportion of 
individuals who screened positive for depression would take up treatment and continue to participate 
in treatment while experiencing depression. An important consideration in the cost-effectiveness of 
treatment is engagement with individuals who have depression to link them up with appropriate 
treatment. Although the intervention may be cost-effective, the impact can only be realised if 
individuals participate in treatment (Corrigan et al., 2014) and this could be influenced by workplace 
characteristics. We know that stigma is an important barrier to getting help for mental illness 
(Clement et al., 2014) and can influence population prevalence of treatment for depression (Lewer et 
al., 2015).  Individuals may choose not to participate in treatment and / or to disclose a mental health 
problem in the workplace because of potentially negative consequences from their employer or 
colleagues (Brohan et al., 2014). Given  that employers and colleagues may be less likely to accept an 
individual who has depression  (Angermeyer et al., 2013; Brohan et al., 2012; Lasalvia et al., 2012), 
managers also have an important role to play in supporting employees and facilitating a positive 
environment. For example, we know that managers who support employees with depression may 
facilitate more positive perceptions in the workplace and more openness and disclosure among 
employees with depression (Evans-Lacko and Knapp, 2014) which could be important for treatment 
participation.  
Strengths and limitations 
There are very few robust economic studies of workplace interventions (Hamberg-van Reenen et al., 
2012). A few studies have performed economic evaluation, but they focus on specific populations, 
for example, correctional officers (McCraty et al., 2009) and nurses (Noben et al., 2014) who may 
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have specific needs; focus on a specific intervention programme, for example, a return to work 
intervention (van Oostrom et al., 2010), collaborative care (Goorden et al., 2014)  or a collaborative 
care approach (Wang et al., 2006) and follow-up is rarely longer than 1 year. Thus, our study adds to 
the literature by applying a 27 month time frame, comparing across 3 types of standard, evidence-
based interventions and considering the impact in relation to the general population of employed 
individuals in Germany.  
Although we believe that our findings are based on the best available evidence, our conclusions are 
based on a simulation model which requires several assumptions and the associated limitations 
need to be considered alongside our conclusions. There are certain costs which were not included in 
the model such as the impact on family members, premature death, recruitment and training costs 
for employers if their employees permanently withdraw from the workforce. We assume that the 
distribution of costs would not vary widely across the treatment conditions; however, they could 
increase the overall costs, particularly for individuals with severe depression who may require more 
support from a carer and be more likely to transition from employment to permanent disability 
status. We have not included disability and early retirement costs in the model which we know are 
increasing (McDaid, 2008) and which could also represent important savings if, for example, 
treatment was likely even to reduce early retirement among a very small proportion of employees. 
Some issues have been noted in previous work regarding direct comparisons of psychotherapy and 
pharmacotherapy treatments given differences in study designs and these should be considered. For 
example, some research suggests that methodological issues such as a nocebo effect associated with 
wait list controls, difficulty in blinding and small study bias may be associated with a higher effect 
size for psychotherapy compared to pharmacotherapy studies (Furukawa et al., 2014; Huhn et al., 
2014). Additionally, our findings may not be relevant for individuals with highly recurrent depressive 
disorder as the length of maintenance treatment needed for these individuals may be longer than 21 
months; however, our upper bound was also driven by the economic case of the maximum amount 
of time for which the insurance company would pay. Finally, there may be significant variation in 
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workplace setting or type of employment and more broadly, region or country. For instance, we 
know that some types of workplace stress are associated with greater levels of depression and these 
might represent particular targets for interventions (Fischer et al. 2001; Michie 2003) and should be 
further explored. Moreover, it is likely that the effects of treatment would be more positive if the 
treatments included a specific work-directed component and or were modified with an employment 
focus (Lagerveld et al., 2012; Nieuwenhuijsen et al., 2014).  
In relation to the global context, although this model is based on a German employment perspective 
which has a specific set of national employment policies, we might assume that some of our findings 
could be broadly relevant for other high-income and / or European countries. However, we should 
also consider the health policy context in relation to generalisability. Germany is funded by a 
statutory contribution system that ensures free health care for all via health insurance funds. 
Insurance payments are based on a percentage of income, shared between employee and 
employer.1  More research should be done across diverse countries to better understand potential 
differences across other settings and contexts. For example, although we know that depression has a 
significant economic impact via workplace productivity globally, the impact and the ratio of costs of 
presenteeism to absenteeism varies across countries (Evans-Lacko and Knapp, 2015). Moreover, 
workplace policies and context, access to appropriate interventions also vary and must be considered.  
Implications 
In order to realise the economic benefits outlined in this paper, there needs to be a better balance 
between the needs of employees with depression in the workplace and the services and 
interventions provided to them. In view of increasing productivity losses attributable to depression 
                                                          
1  Health insurance in Germany is divided between statutory and private schemes. The statutory health 
insurance, the so-called Gesetzliche Krankenversicherung (GKV), occupies a central position in the healthcare 
system in the Federal Republic of Germany. Approximately ninety percent of the population is covered by 
statutory health insurance, which is compulsory for all with a gross income of less than 4,462.50 EUR per 
month. Private healthcare schemes can either provide a complete health service for those who opt out of the 
GKV, or top-up cover for those who remain within it. Further information on health care expenditure in 
Germany can be found here: http://www.gbe-bund.de/pdf/GesInDtldSummary.pdf 
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and the economic consequences associated with this, the need for better workplace policies is 
evident. There are, however, models of good practice available and therefore actions which can be 
taken to improve the workplace context and outcomes for employees and businesses. In general 
three approaches are described in the literature: (1) a focus on earlier intervention to reduce the gap 
between recognition and treatment, (2) support and training for employees, managers and other 
relevant staff and (3) complete support from the top of the organization through enactment of 
supportive policies and practices for both prevention and treatment of depression.  . In relation to 
early intervention, the German AOK programme for treatment of depression and burn-out 
(http://www.kvn.de/Praxis/Fortbildung/AOK-Behandlungsprogramm-Depression-und-Burn-out/) is 
an example of good practice for closing the treatment gap.  The programme improves access 
through enhanced treatment available through the GP practice and access to a specialist or 
psychotherapist within 14 days.  Participating physicians and psychotherapists are paid a separate 
fee for their services and accessibility is increased via opening hours during evenings and weekends 
(AOK 2015).Other initiatives such as the Masto project in Finland, use a multifaceted approach 
involving different administrative sectors, social partners and the third sector to increase wellbeing 
at work, prevent depression, increase early recognition and improve care, rehabilitation and help-
seeking for employees with depression (European Commission, 2015). Nevertheless, it is important 
to consider potential variation across Europe in relation to early intervention both in relation to 
need and delivery of evidence based programmes. The literature suggests that there is some 
variation across Europe in terms of when individuals with mood disorders initiate treatment, with 
only 28% of individuals in Italy initiating treatment during the year of onset while 52% made contact 
in the Netherlands (Wang et al., 2007); however, there is not a clear North – South divide and there 
may be certain country characteristics where a focus on early intervention is of greater need. For 
example, we know that greater health care spending and lower public stigma is associated with 
greater use and regularity of antidepressants (Lewer et al., 2015). 
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It is also now possible to use eHealth technologies to facilitate early recognition of mood problems 
among employees, for example, through mobile apps for monitoring symptoms and web-based 
programmes which can provide an effective form of prevention and treatment. There are also 
opportunities to use technology for training aids or supports for managers and HR staff; however, it 
is critical that a clear pathway to treatment and support is in place if such an intervention were to be 
introduced. 
In relation to support and training for employees, managers and other relevant staff there are good 
examples of tools and supports which enable employers and managers to promote a positive 
psychosocial work environment and support employees with depression. Some companies such as 
Toshiba also use electronic questionnaires to collect regular feedback from employees in the 
organization. Finally, strong support from senior management at the top of the organization can 
help to ensure that adequate policies are put in place and implemented in a meaningful way.  
Policies may focus on supporting employees with depression, their line managers and key support 
figures in the organization such as those working in HR and occupational health.  
A model of good practice, particularly in relation to development and implementation of risk 
assessment and prevention policies is the e-learning tool “Psychological health promotion as a 
leadership task” of the German INQA initiative (INQA 2015). INQA promotes exchanges between 
companies, government and researchers and uses a holistic approach to support companies to 
improve workplace conditions including through tailored tools and measures which facilitate early 
detection of symptoms of burn out and other psychological problems in addition to health 
promotion.  
  
19 
 
Acknowledgments 
We would like to acknowledge Alexander Schubert and Annemieke Heuvink for their support in 
preparing the manuscript and the Expert Platform on mental health focus on depression (EPD) for 
providing an unrestricted educational grant. 
Author Disclosure  
Role of funding source: Funding for this study was provided by the Expert Platform on Mental 
Health – Focus on Depression.  
 
Author contributions: The original study design and protocol was written by SEL and KK with 
contributions from CL, LK and MK. SEL performed data analysis and initial drafting of the manuscript 
with contributions from CL and KK.  All authors participated in interpretation of the analysis, editing 
and rewriting of the manuscript and all authors have approved the final manuscript. 
Competing Interests: SEL and MK received consulting fees from Lundbeck, not connected to this 
research. JZ has received grant/research support from Lundbeck, Servier, Brainsway and Pfizer, has 
served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca 
and Roche, and has served on speakers’ bureaus for Lundbeck, Roch, Lilly Servier, Pfizer and Abbott. 
 
  
20 
 
References 
Angermeyer, M.C., Matschinger, H., Schomerus, G., 2013. Public attitudes towards people with 
depression in times of uncertainty: results from three population surveys in Germany. Soc. 
Psychiatry Psychiatr. Epidemiol. 48, 1513–8. doi:10.1007/s00127-012-0618-2 
Birnbaum, H.G., Kessler, R.C., Kelley, D., Ben-Hamadi, R., Joish, V.N., Greenberg, P.E., 2010. Employer 
burden of mild, moderate, and severe major depressive disorder: mental health services 
utilization and costs, and work performance. Depress. Anxiety 27, 78–89. 
doi:10.1002/da.20580 
Brohan, E., Evans-Lacko, S., Henderson, C., Murray, J., Slade, M., Thornicroft, G., 2014. Disclosure of 
a mental health problem in the employment context: qualitative study of beliefs and 
experiences. Epidemiol. Psychiatr. Sci. 23, 289–300. doi:10.1017/S2045796013000310 
Brohan, E., Henderson, C., Wheat, K., Malcolm, E., Clement, S., Barley, E.A., Slade, M., Thornicroft, 
G., 2012. Systematic review of beliefs, behaviours and influencing factors associated with 
disclosure of a mental health problem in the workplace. BMC Psychiatry 12, 11. 
Churchill, R., Hunot, V., Corney, R., Knapp, M., McGuire, H., Tylee, A., Wessely, S., 2001. A systematic 
review of controlled trials of the effectiveness and cost-effectiveness of brief psychological 
treatments for depression. Health Technol. Assess. 5, 1–173. 
Clement, S., Schauman, O., Graham, T., Maggioni, F., Evans-Lacko, S., Bezborodovs, N., Morgan, C., 
Rüsch, N., Brown, J.S.L., Thornicroft, G., 2014. What is the impact of mental health-related 
stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol. 
Med. 1–17. doi:10.1017/S0033291714000129 
Commission, E., 2015. Mental health compass database of policies and good practices [WWW 
Document]. Masto Proj. to reduce Depress. Relat. Work Disabil. URL 
https://webgate.ec.europa.eu/sanco_mental_health/public/POLICY/422/show.html (accessed 
7.31.15). 
Corrigan, P.W., Druss, B.G., Perlick, D.A., 2014. The Impact of Mental Illness Stigma on Seeking and 
Participating in Mental Health Care. Psychol. Sci. Public Interes. 15, 37–70. 
doi:10.1177/1529100614531398 
Cuijpers, P., Reynolds, C.F., Donker, T., Li, J., Andersson, G., Beekman, A., 2012. Personalized 
treatment of adult depression: medication, psychotherapy, or both? A systematic review. 
Depress. Anxiety 29, 855–64. doi:10.1002/da.21985 
DeRubeis, R.J., Evans, M.D., Hollon, S.D., Garvey, M.J., Grove, W.M., Tuason, V.B., 1990. How does 
cognitive therapy work? Cognitive change and symptom change in cognitive therapy and 
pharmacotherapy for depression. J. Consult. Clin. Psychol. 58, 862–869. doi:10.1037/0022-
006X.58.6.862 
Ekman M, Granstrom O, Omerov S, Jacob J, L.M., 2013. The societal cost of depression: Evidence 
from 10,000 Swedish patients in psychiatric care. J. Affect. Disord. 13, 00227–9. 
Evans-Lacko S., K.M., 2015. Global trends of workplace productivity for people with depression: 
absenteeism and presenteeism costs across eight diverse countries. under Rev. 
Evans-Lacko, S., Knapp, M., 2014. Importance of social and cultural factors for attitudes, disclosure 
and time off work for depression: findings from a seven country European study on depression 
in the workplace. PLoS One 9, e91053. doi:10.1371/journal.pone.0091053 
Ferrari, A.J., Charlson, F.J., Norman, R.E., Patten, S.B., Freedman, G., Murray, C.J.L., Vos, T., 
Whiteford, H.A., 2013. Burden of depressive disorders by country, sex, age, and year: findings 
from the global burden of disease study 2010. PLoS Med. 10, e1001547. 
doi:10.1371/journal.pmed.1001547 
Festbetragsarzneimittel nach 35 SGB V sortiet nach Arzneimittelname [WWW Document], 2015. . 
Dtsch. Inst. fur Medizinische Dokumentation und Inf. URL 
https://www.dimdi.de/static/de/amg/festbetraege-zuzahlung/festbetraege/index.htm 
(accessed 6.10.15). 
21 
 
Fischer, F.M.P., Morata, T.C.P., Latorre, M. do R.P., Krieg, E.F.P., Fiorini, A.C.P., Colacioppo, S.P., 
Gozzoli, L.Bs., Padrao, M.A.Bs., Zavariz, C.P., Lieber, R.P., Wallingford, K.M.M., Cesar, C.L.G.P., 
2001. Effects of Environmental and Organizational Factors on the Health of Shiftworkers of a 
Printing Company. J. Occup. Environ. Med. 43, 882–889. 
Fournier, J.C., DeRubeis, R.J., Amsterdam, J., Shelton, R.C., Hollon, S.D., 2015. Gains in employment 
status following antidepressant medication or cognitive therapy for depression. Br. J. 
Psychiatry 206, 332–8. doi:10.1192/bjp.bp.113.133694 
Furukawa, T.A., Noma, H., Caldwell, D.M., Honyashiki, M., Shinohara, K., Imai, H., Chen, P., Hunot, V., 
Churchill, R., 2014. Waiting list may be a nocebo condition in psychotherapy trials: a 
contribution from network meta-analysis. Acta Psychiatr. Scand. 130, 181–92. 
doi:10.1111/acps.12275 
German Society for Psychiatry, Psychotherapy,  and N. (DGPPN), 2015. S3-Guideline/National 
Disease Management Guideline “Unipolar Depression” [WWW Document]. URL 
www.depression.versorgungsleitlinien.de a (accessed 6.4.15). 
Goldberg, R.J., Steury, S., 2001. Depression in the Workplace: Costs and Barriers to Treatment. 
Psychiatr. Serv. 52, 1639–1643. doi:10.1176/appi.ps.52.12.1639 
Gollier, C., 2011. On the Underestimation of the Precautionary Effect in Discounting*. Geneva Risk 
Insur. Rev. 36, 95–111. doi:10.1057/grir.2011.6 
Goorden, M., Vlasveld, M.C., Anema, J.R., van Mechelen, W., Beekman, A.T.F., Hoedeman, R., van 
der Feltz-Cornelis, C.M., Hakkaart-van Roijen, L., 2014. Cost-utility analysis of a collaborative 
care intervention for major depressive disorder in an occupational healthcare setting. J. Occup. 
Rehabil. 24, 555–62. doi:10.1007/s10926-013-9483-4 
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., 
Faravelli, C., Fratiglioni, L., Gannon, B., Jones, D.H., Jennum, P., Jordanova, A., Jönsson, L., 
Karampampa, K., Knapp, M., Kobelt, G., Kurth, T., Lieb, R., Linde, M., Ljungcrantz, C., Maercker, 
A., Melin, B., Moscarelli, M., Musayev, A., Norwood, F., Preisig, M., Pugliatti, M., Rehm, J., 
Salvador-Carulla, L., Schlehofer, B., Simon, R., Steinhausen, H.-C., Stovner, L.J., Vallat, J.-M., Van 
den Bergh, P., den Bergh, P. Van, van Os, J., Vos, P., Xu, W., Wittchen, H.-U., Jönsson, B., 
Olesen, J., 2011. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 
718–79. doi:10.1016/j.euroneuro.2011.08.008 
Hamberg-van Reenen, H.H., Proper, K.I., van den Berg, M., 2012. Worksite mental health 
interventions: a systematic review of economic evaluations. Occup. Environ. Med. 69, 837–45. 
doi:10.1136/oemed-2012-100668 
Henderson, M., Madan, I., 2014. Mental health and work, in: Davies, S., M.N. (Ed.), Annual Report of 
the Chief Medical Officer 2013, Public Mental Health Priorities: Investing in the Evidence. 
Department of Health, London, pp. 157–169. 
Hollinghurst, S., Carroll, F.E., Abel, A., Campbell, J., Garland, A., Jerrom, B., Kessler, D., Kuyken, W., 
Morrison, J., Ridgway, N., Thomas, L., Turner, K., Williams, C., Peters, T.J., Lewis, G., Wiles, N., 
2014. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy 
for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. Br. 
J. Psychiatry 204, 69–76. doi:10.1192/bjp.bp.112.125286 
Holzhausen M, B., U, F.T., 2009. Patient view in the assessment of quality of life in old age: potentials 
and limits. Zeitschrift fur Gerontol. und Geriatr.  Organ der Dtsch. Gesellschaft fur Gerontol. 
und Geriatr., Die Patientenperspektive in der Erfassung von Lebensqualitat im Alter: 
Moglichkeiten und Grenzen. 
Huhn, M., Tardy, M., Spineli, L.M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., 
Dold, M., Davis, J.M., Leucht, S., 2014. Efficacy of pharmacotherapy and psychotherapy for 
adult psychiatric disorders: a systematic overview of meta-analyses. JAMA psychiatry 71, 706–
15. doi:10.1001/jamapsychiatry.2014.112 
Jacobi, F., Höfler, M., Siegert, J., Mack, S., Gerschler, A., Scholl, L., Busch, M.A., Hapke, U., Maske, U., 
Seiffert, I., Gaebel, W., Maier, W., Wagner, M., Zielasek, J., Wittchen, H.-U., 2014. Twelve-
22 
 
month prevalence, comorbidity and correlates of mental disorders in Germany: the Mental 
Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-
MH). Int. J. Methods Psychiatr. Res. 23, 304–19. doi:10.1002/mpr.1439 
Kassenarztliche Bundesvereinigung, 2015a. Einheitlicher Bewertungsmaßstab - Psychiater. 
Kassenarztliche Bundesvereinigung, 2015b. Einheitlicher Bewertungsmaßstab - 
Psychotherapeutische Medizin. 
Khan, A., Faucett, J., Lichtenberg, P., Kirsch, I., Brown, W.A., 2012. A systematic review of 
comparative efficacy of treatments and controls for depression. PLoS One 7, e41778. 
doi:10.1371/journal.pone.0041778 
Kleine-Budde, K., Müller, R., Kawohl, W., Bramesfeld, A., Moock, J., Rössler, W., 2013. The cost of 
depression - a cost analysis from a large database. J. Affect. Disord. 147, 137–43. 
doi:10.1016/j.jad.2012.10.024 
Knapp, M., McDaid, D., Parsonage, M., 2011. Mental health promotion and prevention: the 
economic case. Personal Social Services Research Unit, London School of Economics and 
Political Science, London, UK. 
Koeser L, Donisi V, Goldberg DP, M.P., 2015. Modelling the cost-effectiveness of pharmacotherapy 
compared to CBT and combination therapy for the treatment of moderate to severe 
depression in the UK. Psychol. Med. 
Kuyken, W., Byford, S., Taylor, R.S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., 
Mullan, E., Teasdale, J.D., 2008. Mindfulness-based cognitive therapy to prevent relapse in 
recurrent depression. J. Consult. Clin. Psychol. 76, 966–78. doi:10.1037/a0013786 
Lagerveld, S.E., Blonk, R.W.B., Brenninkmeijer, V., Wijngaards-de Meij, L., Schaufeli, W.B., 2012. 
Work-focused treatment of common mental disorders and return to work: A comparative 
outcome study. J. Occup. Health Psychol. 17, 220–234. 
Lasalvia, A., Zoppei, S., Van, B.T., Bonetto, C., Cristofalo, D., Wahlbeck, K., Bacle, S. V, Van, A.C., van, 
W.J., Reneses, B., Germanavicius, A., Economou, M., Lanfredi, M., Ando, S., Sartorius, N., 
Lopez-Ibor, J.J., Thornicroft, G., 2012. Global pattern of experienced and anticipated 
discrimination reported by people with major depressive disorder: a cross-sectional survey. 
Lancet. 
Leal, J., Luengo-Fernández, R., Gray, A., Petersen, S., Rayner, M., 2006. Economic burden of 
cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27, 1610–9. 
doi:10.1093/eurheartj/ehi733 
Lewer, D., O’Reilly, C., Mojtabai, R., Evans-Lacko, S., 2015. Antidepressant use in 27 European 
countries: associations with sociodemographic, cultural and economic factors. Br. J. Psychiatry. 
doi:10.1192/bjp.bp.114.156786 
McCraty, R., Atkinson, M., Lipsenthal, L., Arguelles, L., 2009. New hope for correctional officers: an 
innovative program for reducing stress and health risks. Appl. Psychophysiol. Biofeedback 34, 
251–72. doi:10.1007/s10484-009-9087-0 
McDaid, D., 2008. Mental health in workplace settings. Luxembourg. 
Michael, M.D.K.D.P., 2011. Workplace screening for depression and anxiety disorders, in: Knapp 
Martin, McDaid David, P.M. (Ed.), Mental Health Promotion and Prevention: The Economic 
Case. Personal Social Services Research Unit, London School of Economics and Political Science, 
London, UK. 
Michie, S., 2003. Reducing work related psychological ill health and sickness absence: a systematic 
literature review. Occup. Environ. Med. 60, 3–9. doi:10.1136/oem.60.1.3 
NCCMH, 2009. Depression in adults: The treatment and management of depression in adults. 
Nieuwenhuijsen, K., Faber, B., Verbeek, J.H., Neumeyer-Gromen, A., Hees, H.L., Verhoeven, A.C., van 
der Feltz-Cornelis, C.M., Bültmann, U., 2014. Cochrane Database of Systematic Reviews, The 
Cochrane database of systematic reviews. John Wiley & Sons, Ltd, Chichester, UK. 
doi:10.1002/14651858.CD006237.pub3 
Noben, C., Smit, F., Nieuwenhuijsen, K., Ketelaar, S., Gärtner, F., Boon, B., Sluiter, J., Evers, S., 2014. 
23 
 
Comparative cost-effectiveness of two interventions to promote work functioning by targeting 
mental health complaints among nurses: pragmatic cluster randomised trial. Int. J. Nurs. Stud. 
51, 1321–31. doi:10.1016/j.ijnurstu.2014.01.017 
Quilty, L.C., McBride, C., Bagby, R.M., 2008. Evidence for the cognitive mediational model of 
cognitive behavioural therapy for depression. Psychol. Med. 38, 1531–41. 
doi:10.1017/S0033291708003772 
Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, 
G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., 
Kupfer, D.J., Luther, J., Fava, M., 2006. Acute and longer-term outcomes in depressed 
outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 
1905–17. doi:10.1176/appi.ajp.163.11.1905 
Speight, J., Reaney, M., 2009. Wouldn’t it be NICE to consider patients' views when rationing health 
care? BMJ 338, b85–b85. doi:10.1136/bmj.b85 
Techniker Krankenkasse, 2013. Depressionsatlas. 
Thomas CM, M.S., 2003. Cost of depression among adults in England in 2000. Br. J. Psychiatry 183, 
514–519. 
Ubel, P.A., Hirth, R.A., Chernew, M.E., Fendrick, A.M., 2003. What is the price of life and why doesn’t 
it increase at the rate of inflation? Arch. Intern. Med. 163, 1637–41. 
doi:10.1001/archinte.163.14.1637 
van Oostrom, S.H., Heymans, M.W., de Vet, H.C.W., van Tulder, M.W., van Mechelen, W., Anema, 
J.R., 2010. Economic evaluation of a workplace intervention for sick-listed employees with 
distress. Occup. Environ. Med. 67, 603–10. doi:10.1136/oem.2009.051979 
Wang, P.S., Angermeyer, M., Borges, G., Bruffaerts, R., Tat Chiu, W., DE Girolamo, G., Fayyad, J., 
Gureje, O., Haro, J.M., Huang, Y., Kessler, R.C., Kovess, V., Levinson, D., Nakane, Y., Oakley 
Brown, M.A., Ormel, J.H., Posada-Villa, J., Aguilar-Gaxiola, S., Alonso, J., Lee, S., Heeringa, S., 
Pennell, B.-E., Chatterji, S., Ustün, T.B., 2007. Delay and failure in treatment seeking after first 
onset of mental disorders in the World Health Organization’s World Mental Health Survey 
Initiative. World Psychiatry 6, 177–85. 
Wolf, K., 2010. Making the Link between Health and Productivity at the Workplace —A Global 
Perspective. Ind. Health 48, 251–255. 
Wykes, T., Haro, J.M., Belli, S.R., Obradors-Tarragó, C., Arango, C., Ayuso-Mateos, J.L., Bitter, I., 
Brunn, M., Chevreul, K., Demotes-Mainard, J., Elfeddali, I., Evans-Lacko, S., Fiorillo, A., Forsman, 
A.K., Hazo, J.-B., Kuepper, R., Knappe, S., Leboyer, M., Lewis, S.W., Linszen, D., Luciano, M., 
Maj, M., McDaid, D., Miret, M., Papp, S., Park, A.-L., Schumann, G., Thornicroft, G., van der 
Feltz-Cornelis, C., van Os, J., Wahlbeck, K., Walker-Tilley, T., Wittchen, H.-U., 2015. Mental 
health research priorities for Europe. The lancet. Psychiatry 2, 1036–42. doi:10.1016/S2215-
0366(15)00332-6 
 
  
24 
 
Table 1. Cost-effectiveness scenarios for antidepressants vs. psychotherapy vs. combination treatment for employees with depression.  
 
Intervention Costs1 (€) QALYs ICERs (€ / QALY) 
Pharmacotherapy 30,508 1.26 N/A 
CBT 31,397 1.30  22225 
Combination 32,615 1.31  121800 
 
1Productivity losses are treated equivalently to cost of health service use for year 1, dependent on the depression state but not treatment. 
 
 
Table 2. Cost payoffs from an employer based and healthcare perspective for screening and treatment of employees with depression over a 27 month 
timeframe4 
 
 Hypothetical cohort of 
500 employees  
(€) 
Total insured 
population in Germany 3 
(€) 
Pharmacotherapy 
Intervention costs1 41,491 3,136,719,600 
Additional healthcare costs2 26,908 2,034,244,800 
Productivity losses (absenteeism) -37,404 -2,827,742,400 
Productivity losses (presenteeism) -62,097 -4,694,533,200 
Psychotherapy 
Intervention costs 53,515 4045734000 
Additional healthcare costs 26,908 2034244800 
Productivity losses (absenteeism) -38,180 -2,886,408,000 
Productivity losses (presenteeism) -62,097 -4694533200 
 
1 Over 15 month period (3 months acute treatment and 12 months maintenance phase) 
2 Inpatient hospitalisation costs and additional service use costs following 15 month intervention  
3 37.8 million insured employees in Germany (Techniker Krankenkasse, 2013) 
4 We assume for this analysis that the prevalence of mild, moderate and severe depression was  13.8%, 38.5% and 47.7%, respectively. 
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Figure 1. Decision tree model for antidepressant therapy, psychotherapy and combination 
treatment   
 
26 
 
 
